Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

224 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Gathering information about metabolic syndrome from young patients with acute lymphoblastic leukemia may help doctors learn more about the disease.

PURPOSE: This phase I trial is studying the metabolic syndrome in young patients with acute lymphoblastic leukemia in remission.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Metabolic Syndrome in Young Patients Who Are Acute Lymphoblastic Leukemia Survivors and Their Healthy Siblings

NCT00897078

Leukemia

COMPLETED

Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission

NCT00268528

Childhood Acute Lymphoblastic Leukemia in Remission

COMPLETED

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

NCT05082519

B-cell Acute Lymphoblastic Leukemia Obesity

RECRUITING PHASE2

Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate

NCT00898404

B-cell Childhood Acute Lymphoblastic Leukemia Childhood Acute Lymphoblastic Leukemia in Remission Recurrent Childhood Acute Lymphoblastic Leukemia +1 more

COMPLETED

Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia

NCT01057290

Leukemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* To determine the incidence and prevalence of the components of metabolic syndrome (e.g., obesity, hypertension, dyslipidemia, and insulin resistance) in pediatric patients with acute lymphoblastic leukemia in remission.
* To determine the trajectory of the onset of these components over a 1-year period in patients undergoing maintenance therapy.

Secondary

* To identify potential associations between components of metabolic syndrome and fatigue, health-related quality of life, family history, nutrition, and physical activity.
* To identify potential biomarkers that are associated with clinical features of metabolic syndrome.
* To evaluate whether patients will show a decrease in IGF-1 levels.

OUTLINE: This is a two-part study. Patients are enrolled in either part 1 or part 2.

* Part 1: Patients undergo physical exam measurements (e.g., body mass index, waist circumference, and blood pressure) at baseline (during maintenance course 1) and at 12 months (during maintenance course 5). Patients also undergo blood sample collection at baseline and at 12 months to measure laboratory markers (e.g., fasting lipid profile, fasting insulin and glucose, IGF-1, leptin, and adiponectin levels). Patients or their parents complete a family history questionnaire at baseline and questionnaires to assess physical activity, quality of life, nutritional intake, and fatigue at baseline and at 6 and 12 months.
* Part 2: Patients or their parents complete a family history questionnaire at baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatigue Leukemia Long-term Effects Secondary to Cancer Therapy in Children

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laboratory biomarker analysis

Intervention Type OTHER

metabolic assessment

Intervention Type OTHER

questionnaire administration

Intervention Type OTHER

assessment of therapy complications

Intervention Type PROCEDURE

fatigue assessment and management

Intervention Type PROCEDURE

quality-of-life assessment

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

Part 1

* Diagnosis of precursor B-cell acute lymphoblastic leukemia (ALL)

* In first remission
* In first 3 months of maintenance therapy
* No T-cell ALL, very high-risk ALL, or infant ALL (\< 1 year old at diagnosis)

Part 2

* Diagnosis of precursor B-cell or T-cell ALL

* In first remission
* Must have been diagnosed and treated (at least to the maintenance phase) at the Division of Pediatric Oncology at the Vanderbilt-Ingram Cancer Center within the past 7 years
* No very high-risk ALL or infant ALL (\< 1 year old at diagnosis)

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior or concurrent cranial radiotherapy (Part 1)

Minimum Eligible Age

1 Year

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No